Abbott Board of Directors Approves Separation of AbbVie and Declares Special Dividend Distribution of AbbVie Stock

 Abbott Board of Directors Approves Separation of AbbVie and Declares Special
                    Dividend Distribution of AbbVie Stock

  PR Newswire

  ABBOTT PARK, Illinois, Nov. 28, 2012

ABBOTT PARK, Illinois, Nov. 28, 2012 /PRNewswire/ -- Abbott (NYSE: ABT)
announced today that its board of directors has approved the separation of its
research-based pharmaceuticals business, which will be known as AbbVie Inc.,
and declared a special dividend distribution of all of the outstanding shares
of AbbVie common stock.

For every 1 share of Abbott common shares held, Abbott shareholders will
receive 1 share of AbbVie common stock. No fractional shares of AbbVie will be
issued. Shareholders will receive cash in lieu of fractional shares. The
special dividend distribution is expected to be paid on Jan. 1, 2013, to
Abbott shareholders of record as of the close of business on Dec. 12, 2012.

The distribution of AbbVie common stock will complete the separation of the
research-based pharmaceuticals business from Abbott. After the distribution,
AbbVie will be an independent, publicly-traded company and Abbott will retain
no ownership interest. AbbVie common stock is expected to begin trading on
Jan. 2, 2013, on the New York Stock Exchange (NYSE) under the ticker symbol
ABBV. Abbott will continue to trade on the NYSE under the ticker symbol ABT.

"Today's announcement marks another important milestone toward the completion
of our business separation," said Miles D. White, chairman and chief executive
officer, Abbott. "Abbott and AbbVie are well-positioned to begin 2013 as
leaders in their respective markets."

Distribution of the stock dividend is subject to the Securities and Exchange
Commission (SEC) having declared effective AbbVie's Registration Statement on
Form 10, as amended, which AbbVie has filed with the SEC and is available at
http://www.abbottinvestor.com . The special dividend distribution is subject
to the conditions set forth in the Separation and Distribution Agreement
between Abbott and AbbVie, filed as an exhibit to AbbVie's Registration
Statement on Form 10.

Abbott has received a private ruling from the U.S. Internal Revenue Service,
for U.S. federal income tax purposes, that the distribution of AbbVie common
stock is tax-free to U.S. holders of Abbott common stock. However, cash
received in lieu of fractional shares may be taxable to such holders.

No action is required by Abbott shareholders in order to receive shares of
AbbVie common stock in the distribution. Abbott expects to mail the
information statement to all shareholders entitled to receive the distribution
of shares of AbbVie common stock in mid-December. The information statement is
an exhibit to AbbVie's Registration Statement on Form 10 that describes
AbbVie, including the risks of owning AbbVie common stock, and other details
regarding the separation.

AbbVie will be a research-based specialty biopharmaceuticals company with a
broad portfolio of medicines, including leadership in immunology and virology,
and a pipeline of breakthrough therapies. Abbott will be one of the largest
science-based healthcare companies with diversified market-leading offerings
in diagnostics, medical devices, nutritionals and branded generic
pharmaceuticals – all aligned with favorable healthcare trends.

About Abbott Abbott is a global, broad-based health care company devoted to
the discovery, development, manufacture and marketing of pharmaceuticals and
medical products, including nutritionals, devices and diagnostics. The company
employs approximately 91,000 people and markets its products in more than 130
countries.

Abbott's news releases and other information are available on the company's
Web site at www.abbott.com .

– Private Securities Litigation Reform Act of 1995 –

A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for
purposes of the Private Securities Litigation Reform Act of 1995, including
the planned separation of the research-based pharmaceutical company from the
diversified medical products company and the expected financial results of the
two companies after the separation. Abbott cautions that these forward-looking
statements are subject to risks and uncertainties that may cause actual
results to differ materially from those indicated in the forward-looking
statements. Economic, competitive, governmental, technological and other
factors that may affect Abbott's operations are discussed in Item 1A, "Risk
Factors," to our Annual Report on Securities and Exchange Commission Form 10-K
for the year ended Dec. 31, 2011 and in Item 1A, "Risk Factors," to our
quarterly report on Securities and Exchange Commission Form 10-Q for the
quarter ended September 30, 2012 and June 30, 2012, and are incorporated by
reference. Abbott undertakes no obligation to release publicly any revisions
to forward-looking statements as a result of subsequent events or
developments, except as required by law.

Website: http://www.abbott.com
Contact: Media: Melissa Brotz, +1-847-935-3456, or Scott Stoffel,
+1-847-936-9502, or Financial: Brian Yoor, +1-847-937-6343, or Larry Peepo,
+1-847-935-6722